祥翊製藥股份有限公司創立於民國94年，初期以開發505(b)2新藥為目標，其療效主要為改善頭頸癌病患對放療及化療的副作用，增加頭頸癌病患對放化療的耐受度以完成預訂的療程，進而降低頭頸癌病患的局部癌症轉移並增加存活率及存活時間
Investors 2
| Date | Name | Website |
| - | YFY Biotec... | tgbfund.co... |
| - | Birch Vent... | birchvc.co... |
Mentions in press and media 1
| Date | Title | Description |
| 24.07.2026 | Sunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate Matter | Summary Company Announcement Date: July 24, 2026 FDA Publish Date: July 24, 2026 Product Type: Drugs Reason for Announcement: Recall Reason Description Presence of particulate matter identified as steel Company Name: Sunny Pharmtech, Inc. B... |